{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:15:49Z","timestamp":1794651349713,"version":"4.9.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Refractory chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation remains a leading cause of late morbidity and mortality among transplant survivors. Therapeutic targeting of the Janus kinase (JAK)\u2013STAT pathway has proved to be an effective approach for cGVHD; however, toxicities and short response durability have limited the use of available agents. The safety and efficacy of the JAK 1\/2 inhibitor baricitinib were investigated in patients with severe cGVHD refractory to at least 2 lines of therapy. This single-center phase 1\/2 study enrolled 24 adult patients who received 2 dose levels (DLs) of baricitinib, 2 and 4 mg daily, in an intrapatient dose escalation study design. No dose-limiting toxicities were observed at either DL. Overall response rate at 6 months was 76.2% (95% confidence interval [CI], 52.8-91.8), with responses observed across all involved organs, including sclerotic skin and pulmonary. Median failure-free survival was 19 months (95% CI, 11-26), with no deaths or malignancy relapse on treatment. Clinically meaningful improvements in patient-reported and functional outcomes were seen in this highly morbid cohort. Immune correlative studies showed that baricitinib induced significant reductions in cytokine-induced signaling (STAT phosphorylation) in both CD4+ and CD8+ T cells and in proinflammatory cytokine secretion. Baricitinib was well tolerated and exhibited a high rate of durable responses in a cohort of patients with severe cGVHD, warranting further evaluation in earlier-line and larger-scale studies. This trial was registered at www.clinicaltrials.gov as NCT02759731.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018898","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:58:52Z","timestamp":1779879532000},"page":"5751-5761","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1\/2 study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5706-1109","authenticated-orcid":false,"given":"Noa G.","family":"Holtzman","sequence":"first","affiliation":[{"name":"1Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"},{"name":"2Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Im","sequence":"additional","affiliation":[{"name":"3Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"},{"name":"4Division of Hematology-Oncology, University of Pittsburgh\/UPMC Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Curtis","sequence":"additional","affiliation":[{"name":"3Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-4592","authenticated-orcid":false,"given":"Eduard","family":"Schulz","sequence":"additional","affiliation":[{"name":"1Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"},{"name":"5Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubina","family":"Sharma","sequence":"additional","affiliation":[{"name":"6Oral Immunobiology Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-0211","authenticated-orcid":false,"given":"Filip","family":"Pirsl","sequence":"additional","affiliation":[{"name":"1Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Berman","sequence":"additional","affiliation":[{"name":"1Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-2176","authenticated-orcid":false,"given":"Alen","family":"Ostojic","sequence":"additional","affiliation":[{"name":"1Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-6295","authenticated-orcid":false,"given":"M. Teresa","family":"Magone de Quadros Costa","sequence":"additional","affiliation":[{"name":"7National Eye Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1918-4324","authenticated-orcid":false,"given":"Edward W.","family":"Cowen","sequence":"additional","affiliation":[{"name":"8Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4472-9974","authenticated-orcid":false,"given":"Jacqueline","family":"Mays","sequence":"additional","affiliation":[{"name":"6Oral Immunobiology Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leora E.","family":"Comis","sequence":"additional","affiliation":[{"name":"9Department of Rehabilitation Medicine, NIH Clinical Center, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galen","family":"Joe","sequence":"additional","affiliation":[{"name":"9Department of Rehabilitation Medicine, NIH Clinical Center, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-3473","authenticated-orcid":false,"given":"Cody","family":"Peer","sequence":"additional","affiliation":[{"name":"10Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-5613","authenticated-orcid":false,"given":"William","family":"Figg","sequence":"additional","affiliation":[{"name":"10Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Rose","sequence":"additional","affiliation":[{"name":"3Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"El Jurdi","sequence":"additional","affiliation":[{"name":"1Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0560-3174","authenticated-orcid":false,"given":"Marie","family":"Pouzolles","sequence":"additional","affiliation":[{"name":"11Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Hakim","sequence":"additional","affiliation":[{"name":"3Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Taylor","sequence":"additional","affiliation":[{"name":"11Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Z.","family":"Pavletic","sequence":"additional","affiliation":[{"name":"1Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"26","key":"2026090811323500800_bib1","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"2026090811323500800_bib2","first-page":"817","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2020 highly morbid forms report","volume":"27","author":"Wolff","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"19","key":"2026090811323500800_bib3","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2026090811323500800_bib4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"2026090811323500800_bib5","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2026090811323500800_bib6","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","volume":"41","author":"Kitko","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026090811323500800_bib7","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"issue":"87","key":"2026090811323500800_bib8","doi-asserted-by":"crossref","first-page":"35721","DOI":"10.18632\/oncotarget.26291","article-title":"Targeting IFNGR\/IL6R or downstream JAK1\/JAK2 to control GvHD","volume":"9","author":"Ashami","year":"2018","journal-title":"Oncotarget"},{"issue":"11","key":"2026090811323500800_bib9","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/s41375-018-0123-z","article-title":"Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease","volume":"32","author":"Choi","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2026090811323500800_bib10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41375-021-01360-9","article-title":"Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR","volume":"36","author":"Kim","year":"2022","journal-title":"Leukemia"},{"issue":"18","key":"2026090811323500800_bib11","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"2026090811323500800_bib12","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/kex489","article-title":"Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"13","key":"2026090811323500800_bib13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2026090811323500800_bib14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s40744-021-00317-9","article-title":"Efficacy of long-term treatment with once-daily baricitinib 2 mg in patients with active rheumatoid arthritis: post hoc analysis of two 24-week, phase III, randomized, controlled studies and one long-term extension study","volume":"8","author":"Wells","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"9","key":"2026090811323500800_bib15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2026090811323500800_bib16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"17","key":"2026090811323500800_bib17","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/bloodadvances.2024013233","article-title":"Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation","volume":"8","author":"Pidala","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2026090811323500800_bib18","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.bbmt.2011.04.002","article-title":"A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change","volume":"17","author":"Mitchell","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2026090811323500800_bib19","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.4049\/jimmunol.166.8.5208","article-title":"Regulatory effects of eotaxin on acute lung inflammatory injury","volume":"166","author":"Guo","year":"2001","journal-title":"J Immunol"},{"issue":"9","key":"2026090811323500800_bib20","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.4049\/jimmunol.1601054","article-title":"Upregulation of IFN-inducible and damage-response pathways in chronic graft-versus-host disease","volume":"197","author":"Hakim","year":"2016","journal-title":"J Immunol"},{"issue":"9","key":"2026090811323500800_bib21","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1097\/TP.0000000000005345","article-title":"Chronic graft-versus-host disease, part 2: clinical success and roadmap to the future","volume":"109","author":"El Jurdi","year":"2025","journal-title":"Transplantation"},{"issue":"suppl 1","key":"2026090811323500800_bib22","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2022-157214","article-title":"Phase I study of baricitinib Gvhd prophylaxis in HLA-matched, peripheral blood allogeneic hematopoietic cell transplant","volume":"140","author":"Schroeder","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026090811323500800_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"2026090811323500800_bib24","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/art.40680","article-title":"Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis","volume":"70","author":"Tanaka","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026090811323500800_bib25","doi-asserted-by":"crossref","first-page":"932240","DOI":"10.3389\/fimmu.2022.932240","article-title":"Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes","volume":"13","author":"Tucci","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"2026090811323500800_bib26","first-page":"657","article-title":"Current definitions and clinical implications of biomarkers in graft-versus-host disease","volume":"28","author":"Bidgoli","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"17","key":"2026090811323500800_bib27","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1182\/bloodadvances.2022007611","article-title":"Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD","volume":"7","author":"Buxbaum","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2026090811323500800_bib28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1078-0432.CCR-15-1443","article-title":"A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation","volume":"22","author":"Arai","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2026090811323500800_bib29","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2012-06-438911","article-title":"B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways","volume":"120","author":"Allen","year":"2012","journal-title":"Blood"},{"key":"2026090811323500800_bib30","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3389\/fimmu.2018.01510","article-title":"Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system","volume":"9","author":"Kubo","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"2026090811323500800_bib31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbmt.2014.11.010","article-title":"CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease","volume":"21","author":"Greinix","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2026090811323500800_bib32","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood-2013-08-520072","article-title":"Plasma CXCL9 elevations correlate with chronic GVHD diagnosis","volume":"123","author":"Kitko","year":"2014","journal-title":"Blood"},{"key":"2026090811323500800_bib33","doi-asserted-by":"crossref","first-page":"995149","DOI":"10.3389\/fimmu.2022.995149","article-title":"BAFF blockade attenuates acute graft-versus-host disease directly via the dual regulation of T- and B-cell homeostasis","volume":"13","author":"Jeon","year":"2022","journal-title":"Front Immunol"},{"issue":"Pt B","key":"2026090811323500800_bib34","doi-asserted-by":"crossref","first-page":"107598","DOI":"10.1016\/j.intimp.2021.107598","article-title":"MCP-1: function, regulation, and involvement in disease","volume":"101","author":"Singh","year":"2021","journal-title":"Int Immunopharmacol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5751\/2541060\/blooda_adv-2025-018898-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5751\/2541060\/blooda_adv-2025-018898-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:32:39Z","timestamp":1788881559000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5751\/568737\/Baricitinib-for-refractory-chronic-graft-versus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":34,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018898","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,26]]}}}